Catalog No.
PMD62601
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse CD124/IL4R/IL-4Rα (Glu31-His225).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
Purification
Purified by antigen affinity column.
Accession
Q544A9
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Dupilumab: Mechanism of action, clinical, and translational science., PMID:39080841
Increased Muc5AC and Decreased Ciliated Cells in Severe Asthma Partially Restored by Inhibition of IL-4Rα Receptor., PMID:38935626
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma., PMID:38871183
IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease., PMID:38704098
Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps., PMID:38603825
Global IL4Rα blockade exacerbates heart failure after an ischemic event in mice and humans., PMID:38426866
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling., PMID:38081297
Th2 cytokine signaling through IL-4Rα increases eotaxin-3 secretion and tension in human esophageal smooth muscle., PMID:37933466
Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis., PMID:37849431
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis., PMID:37032440
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases., PMID:36445014
GWAS Identified IL4R and the Major Histocompatibility Complex Region as the Associated Loci of Total Serum IgE Levels in 9,260 Japanese Individuals., PMID:33864772
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma., PMID:33863808
Polymorphisms of interleukin 4 and interleukin 4 receptor genes and bronchial asthma risk among Egyptian children., PMID:33861987
Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis., PMID:33610558
Molecular mechanism of asthma and its novel molecular target therapeutic agent., PMID:33549541
Human marginal zone B cell development from early T2 progenitors., PMID:33538776
Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade., PMID:33483337
Biologics for Atopic Dermatitis., PMID:33012322
Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis., PMID:33012318
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic., PMID:32534081
Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab., PMID:32490817
Inhibitory effect of IQ-1S, a selective c-Jun N-terminal kinase (JNK) inhibitor, on phenotypical and cytokine-producing characteristics in human macrophages and T-cells., PMID:32315671
Severe asthma: what is new in the new millennium., PMID:32004177
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?, PMID:31863534
Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis., PMID:31603635
Antagonism of the interleukin 4 receptor α promotes TH 1-signalling among T cells from patients with atopic dermatitis after stimulation., PMID:31596502
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis., PMID:31593702
The IL-13-OVOL1-FLG axis in atopic dermatitis., PMID:31509236
A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease., PMID:31269967
Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study., PMID:31187925
Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity., PMID:31123339
CD45Rb-low effector T cells require IL-4 to induce IL-10 in FoxP3 Tregs and to protect mice from inflammation., PMID:31120919
Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesis., PMID:31063025
Possible pathogenic roles of nitric oxide in asthma., PMID:31023598
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma., PMID:30961951
Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4Rα therapeutic antibody., PMID:30950681
Treatment of severe persistent asthma with IL-6 receptor blockade., PMID:30885880
Conjunctivitis in dupilumab clinical trials., PMID:30851191
Towards personalized treatment in atopic dermatitis., PMID:30768375
Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab., PMID:30719708
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials., PMID:30719707
Serum IgE and Allergy Related Genotypes of IL-4R α and IL-13 Genes: Association with Glioma Susceptibility and Glioblastoma Prognosis., PMID:30242995
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma., PMID:30138668
Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis., PMID:30005097
Eosinophilic annular erythema treated with dupilumab., PMID:29790187
Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata., PMID:29710431
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis., PMID:29472119
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma., PMID:29355679
Recent advances in atopic dermatitis., PMID:29273133
For research use only. Not for human or drug use.
